Intellegens and CPI awarded £1.6m Innovate UK grant to advance manufacture of oligonucleotide therapeutics with machine learning

Intellegens, a company applying machine learning (ML) to accelerate innovation in R&D, has secured a £1.6m grant from Innovate UK, part of UK Research and Innovation (UKRI), to apply ML in the emerging field of oligonucleotide therapies. In collaboration with the Centre for Process Innovation (CPI), the two-year project will augment and validate the company’s ML technology, Alchemite™, as a tool to enhance productivity and yields of oligonucleotide therapeutic manufacture through performance prediction and optimisation of quality control strategies.

Recipharm partners with Ahead Therapeutics to develop rare autoimmune disease therapy

About Recipharm Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical and biopharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical and biologics product development, and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK, and the US and is headquartered in Stockholm, Sweden. For more information on Recipharm and our services, please visit www.recipharm.com About Ahead Therapeutics Ahead Therapeutics is a start-up biotech company that uses proprietary technology to develop treatments for different autoimmune disorders. Ahead Therapeutics has developed an innovative solution based on the use of PS-liposomes containing autoantigens. These liposomes can induce antigen-specific immune tolerance through a biomimetic process, thereby interrupting the autoimmune reaction. Simply by changing the encapsulated autoantigen, Ahead’s technology can address the treatment of different auto-immune diseases: Type 1 Diabetes; Multiple Sclerosis; and Celiac Diseases, among others. For more information, please visit www.aheadtherapeutics.com Recipharm AB Corporate identity number 556498-8425 Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00 www.recipharm.com

Cleveland Diagnostics Announces Prostate Cancer Awareness Month Campaign: ‘A PSA on PSA’

National Initiative to Educate Patients, Drive Awareness, & Raise Funds for ZERO Prostate Cancer; Donation Made for Every Fact Sheet Downloaded at PSAonPSA.com

CD Genomics Revolutionizes Pathogen Discovery with the Launch of Viral Metagenomic Sequencing Service

CD Genomics Launches Mature HLA Typing Solutions Enabling Precision Immune Profiling

Watson-Marlow cased pumps for biotechnology

A.C. Camargo Cancer Center Harnesses the Power of DoseMe Precision Dosing Platform to Substantially Reduce Toxicity and Kidney Injuries

oseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced AC Camargo Cancer Center continues to recognize improved patient care with real world data dosing results.

CD Genomics Unveils A Pioneering Genomics Approach—Long Amplicon Analysis (LAA) Service

Breaking Ground: CD Formulation announces 90+ Active Pharmaceutical Ingredients Lineup

Creative Biolabs Updated Autoantigen Microarray Solution to Fuel Autoimmune Research

Creative Biolabs updated its NAA solution, which was designed to provide invaluable insights into autoimmune diseases and autoantibody profiling and promises to propel the field of autoimmune research forward.

BOC Sciences Introduces a Novel XDC Bioconjugation Platform to Advance Biomedical Research

BOC Sciences, a leading supplier of research chemicals and custom services, has unveiled its innovative XDC bioconjugation platform, providing a significant tool for drug delivery.

Alfa Chemistry Leads the Way in Tailored Preclinical Drug Research Solutions

IntelliGuard Appoints Robert Howard as CEO and Thomas Koning as President to Execute on Strategy of Continued Growth

IntelliGuard, a provider of medication and inventory management solutions, is strengthening its leadership team with the appointment of Bob Howard as Chief Executive Officer and Tom Koning as President. Founded in 2006, San Diego-based IntelliGuard provides hospitals with a more efficient and effective system for tracking, tracing, and managing medications and critical inventory to improve patient safety. Their approach to inventory management is particularly relevant right now with ongoing drug shortages.

Multi-protein Expression Service in Insect Cells Now Available at Profacgen

Creative BioMart Updated Its R-PEAPC Conjugated Proteins for Research Use

Creative Proteomics Debuts Far-Western Blot Analysis Service to Advance Proteomics Research

Creative Proteomics Launches Advanced Exosome Isolation and Purification Service

Exploring New Frontiers in Drug Delivery: CD Formulation Introduces State-of-the-Art Microsphere and Microneedle Technologies

Alfa Chemistry Launches a New Blog Section: Sharing Chemical Uses, Chemistry Information and News

Fast Company Names Linus Health’s DCTclock™ a Winner in 2023 Innovation by Design Awards

Revolutionary Digital Cognitive Assessment Recognized for Exceptional User Experience